Literature DB >> 26327756

Epidemiology of hepatitis C in Croatia in the European context.

Tatjana Vilibic-Cavlek1, Jasmina Kucinar1, Bernard Kaic1, Maja Vilibic1, Nenad Pandak1, Ljubo Barbic1, Vladimir Stevanovic1, Jasmina Vranes1.   

Abstract

We analyzed prevalence, risk factors and hepatitis C virus (HCV) genotype distribution in different population groups in Croatia in the context of HCV epidemiology in Europe, with the aim to gather all existing information on HCV infection in Croatia which will be used to advise upon preventive measures. It is estimated that 35000-45000 of the Croatian population is chronically infected with HCV. Like in other European countries, there have been changes in the HCV epidemiology in Croatia over the past few decades. In some risk groups (polytransfused and hemodialysis patients), a significant decrease in the HCV prevalence was observed after the introduction of routine HCV screening of blood/blood products in 1992. Injecting drug users (IDUs) still represent a group with the highest risk for HCV infection with prevalence ranging from 29% to 65%. Compared to the prevalence in the Croatian general population (0.9%), higher prevalence rates were found in prison populations (8.3%-44%), human immunodeficiency virus-infected patients (15%), persons with high-risk sexual behavior (4.6%) and alcohol abusers (2.4%). Low/very low prevalence was reported in children and adolescents (0.3%) as well as in blood donors (0%-0.009%). In addition, distribution of HCV genotypes has changed due to different routes of transmission. In the general population, genotypes 1 and 3 are most widely distributed (60.4%-79.8% and 12.9%-47.9%, respectively). The similar genotype distribution is found in groups with high-risk sexual behavior. Genotype 3 is predominant in Croatian IDUs (60.5%-83.9%) while in the prison population genotypes 3 and 1 are equally distributed (52.4% and 47.6%). Data on HCV prevalence and risk factors for transmission are useful for implementation of preventive measures and HCV screening.

Entities:  

Keywords:  Croatia; Europe; Genotypes; Hepatitis C; Seroprevalence

Mesh:

Year:  2015        PMID: 26327756      PMCID: PMC4548109          DOI: 10.3748/wjg.v21.i32.9476

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  196 in total

1.  Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey.

Authors:  A R Weild; O N Gill; D Bennett; S J Livingstone; J V Parry; L Curran
Journal:  Commun Dis Public Health       Date:  2000-06

2.  Prevalence and significance of hepatitis C virus (HCV) genotypes in anti-HCV positive patients in northwest Croatia.

Authors:  D Golubić; B Vurusić; H H Kessler
Journal:  Acta Med Croatica       Date:  1997

3.  Modified range of alanine aminotransferase is insufficient for screening of hepatitis C virus infection in hemodialysis patients.

Authors:  Irena Milotic; Ivica Pavic; Ivica Maleta; Biserka Troselj-Vukic; Franko Milotic
Journal:  Scand J Urol Nephrol       Date:  2002

4.  Screening for hepatitis B, C and HIV infection among patients on haemodialysis (cross sectional analysis among patients from two dialysis units in the period January to July 2005).

Authors:  G Bosevska; G Kuzmanovska; A Sikole; P Dzekova-Vidimilski; M Polenakovic
Journal:  Prilozi       Date:  2009-12

5.  The prevalence of the owner of serologic markers for the hepatitis C virus, in a north-eastern territory of Romania.

Authors:  D Azoicăi; A Ivan; E Carasievici; V Luca; D Ilcenco; L Scripcaru; D Scripcariu; M Grigoriu-Merchez
Journal:  Rev Med Chir Soc Med Nat Iasi       Date:  2001 Jan-Mar

6.  Hepatitis C in the general adult population of Oslo: prevalence and clinical spectrum.

Authors:  O Dalgard; S Jeansson; K Skaug; N Raknerud; H Bell
Journal:  Scand J Gastroenterol       Date:  2003-08       Impact factor: 2.423

7.  Occupational exposures in healthcare workers in University Hospital Dubrava--10 year follow-up study.

Authors:  Tihana Serdar; Lovorka Derek; Adriana Unić; Domagoj Marijancević; Durda Marković; Ana Primorac; Mladen Petrovecki
Journal:  Cent Eur J Public Health       Date:  2013-09       Impact factor: 1.163

8.  Population-based study on the seroprevalence of hepatitis A, B, and C virus infection in Amsterdam, 2004.

Authors:  G G G Baaten; G J B Sonder; N H T M Dukers; R A Coutinho; J A R Van den Hoek
Journal:  J Med Virol       Date:  2007-12       Impact factor: 2.327

9.  Viral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake.

Authors:  Christiane Sybille Schmidt; Daniela Schön; Bernd Schulte; Stefan Lüth; Susanne Polywka; Jens Reimer
Journal:  J Addict Med       Date:  2013 Nov-Dec       Impact factor: 3.702

10.  Epidemiology of hepatitis C virus (HCV) infection.

Authors:  Theodore Sy; M Mazen Jamal
Journal:  Int J Med Sci       Date:  2006-04-01       Impact factor: 3.738

View more
  4 in total

1.  How close are we to hepatitis C virus elimination in Central Europe?

Authors:  Robert Flisiak; Sona Frankova; Ivica Grgurevic; Bela Hunyady; Peter Jarcuska; Limas Kupčinskas; Michael Makara; Marieta Simonova; Jan Sperl; Ieva Tolmane; Adriana Vince; Dorota Zarębska-Michaluk
Journal:  Clin Exp Hepatol       Date:  2020-02-17

Review 2.  Hepatotropic viruses: Is Roma population at risk?

Authors:  Anna Mrzljak; Lucija Bajkovec; Tatjana Vilibic-Cavlek
Journal:  World J Gastroenterol       Date:  2021-01-14       Impact factor: 5.742

3.  Molecular Epidemiology and Baseline Resistance of Hepatitis C Virus to Direct Acting Antivirals in Croatia.

Authors:  Petra Simicic; Anamarija Slovic; Leona Radmanic; Adriana Vince; Snjezana Zidovec Lepej
Journal:  Pathogens       Date:  2022-07-19

Review 4.  HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons.

Authors:  Robert Flisiak; Dorota Zarębska-Michaluk; Egle Ciupkeviciene; Sylvia Drazilova; Sona Frankova; Ivica Grgurevic; Bela Hunyady; Peter Jarcuska; Limas Kupčinskas; Michael Makara; Gunita Saulite-Vanaga; Marieta Simonova; Jan Sperl; Ieva Tolmane; Adriana Vince
Journal:  Viruses       Date:  2022-02-26       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.